Drug
Avelumab clinical trials
Also written Bavencio and MSB0010718C.
- studies test it
- 201
- open now
- 16
- in phase 3
- 15
- first study started
- 2013
Keep track of what changes. Save the avelumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Bavencio
- 63
Development codes
Studies by the year they started
201 studies that test it; most in 2018 (56)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 6 |
| 2016 | 10 |
| 2017 | 49 |
| 2018 | 56 |
| 2019 | 26 |
| 2020 | 21 |
| 2021 | 7 |
| 2022 | 10 |
| 2023 | 2 |
| 2024 | 6 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 5
- Phase 1
- 80
- Phase 2
- 146
- Phase 3
- 15
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 68 · Other 133
ImmunityBio, Inc. (22) · Pfizer (14) · EMD Serono Research & Development Institute, Inc. (13) · National Cancer Institute (NCI) (9) · M.D. Anderson Cancer Center (5) · Memorial Sloan Kettering Cancer Center (5) · Gruppo Oncologico del Nord-Ovest (4) · Royal Marsden NHS Foundation Trust (3)
Often tested with
Tested in the same studies.
Cyclophosphamide (23) · Nogapendekin alfa inbakicept (22) · Paclitaxel (22) · Fluorouracil (21) · Leucovorin (19) · Capecitabine (18) · Albumin-Bound Paclitaxel (18) · ETBX-061 (17)
Studies
Open first, then newest update. How each study uses avelumab is read from its arms, and is right about nine times in ten.
Testing it · 201
- Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)RecruitingPhase 2National Cancer Institute (NCI)NCT06228066Written as Avelumab
- DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile CarcinomaRecruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT07110038Written as Avelumab
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Avelumab
- Drug Screening Using IMD in Bladder CancerEnrolling by invitationEarly Phase 1Brigham and Women's HospitalNCT06204614Written as Avelumab
- Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial CancerRecruitingPhase 2Queen Mary University of LondonNCT06892860Written as Avelumab
- Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial CarcinomaNot yet recruitingPhase 2Gruppo Oncologico Italiano di Ricerca ClinicaNCT07460245Written as Avelumab 800 mg flat-dose IV
- Avelumab and M1774 in ARID1A-mutated Endometrial CancerRecruitingPhase 2Panagiotis Konstantinopoulos, MD, PhDNCT06518564Written as Avelumab
- Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUCRecruitingPhase 2Samsung Medical CenterNCT07225374Written as Avelumab 10 mg/kg
- TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial CarcinomaRecruitingPhase 2Centre Francois BaclesseNCT04678362Written as Talazoparib + Avelumab
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181Written as Avelumab
- Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.RecruitingPhase 2Gruppo Oncologico del Nord-OvestNCT06869473Written as Cetuximab/avelumab
- Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line TreatmentRecruitingPhase 1/2Hospices Civils de LyonNCT04396223Written as Avelumab Injection
- CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge StrategyRecruitingPhase 2University of Campania Luigi VanvitelliNCT05291156Written as Avelumab
- Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial CancerRecruitingPhase 2Erasmus Medical CenterNCT05600127Written as Avelumab
- A Phase I/II Study of Regorafenib Plus Avelumab in Solid TumorsRecruitingPhase 1/2Institut BergoniéNCT03475953Written as Phase 1 : Avelumab
- Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell CarcinomaRecruitingPhase 1/2Kartos Therapeutics, Inc.NCT03787602Written as Avelumab
- A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based ChemotherapyActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03076554Written as Avelumab
- Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast CancerActive, not recruitingPhase 2Abramson Cancer Center at Penn MedicineNCT04841148Written as Avelumab
- Immunotherapy in Combination With Chemotherapy in Small-cell Lung CancerCompletedPhase 2Hellenic Cooperative Oncology GroupNCT03568097Written as Avelumab
- Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1Active, not recruitingPhase 1TILT Biotherapeutics Ltd.NCT05222932Written as Avelumab
See all 201 studies that test avelumab →
Given in every arm · 38 — avelumab is usual care beside what is tested
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingPhase 2NRG OncologyNCT05327686Written as Avelumab
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerRecruitingPhase 1/2Aulos Bioscience, Inc.NCT05267626Written as Avelumab
- Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced MalignanciesActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT03217747Written as Avelumab
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingActive, not recruitingPhase 3PfizerNCT05059522Written as Avelumab
- Trial of INI-4001 in Patients With Advanced Solid TumoursCompletedPhase 1Inimmune CorporationNCT06302426Written as Avelumab
- Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04068194Written as Avelumab
- Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell LymphomaCompletedPhase 1City of Hope Medical CenterNCT03440567Written as Avelumab
- Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV StudyActive, not recruitingPhase 3National Cancer Institute (NCI)NCT05092958Written as Avelumab
- Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast CancerActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03573648Written as Avelumab
- Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)CompletedPhase 1EMD Serono Research & Development Institute, Inc.NCT05396833Written as Avelumab
- Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial CancerActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT02912572Written as Avelumab
- A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic CancersActive, not recruitingPhase 1iOncturaNCT04328844Written as Avelumab Injection
- Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell CancerActive, not recruitingPhase 2Alliance for Clinical Trials in OncologyNCT03944941Written as Avelumab
- EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck CancerCompletedPhase 2University College, LondonNCT03494322Written as Avelumab
- Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT04902040Written as Avelumab
- Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerActive, not recruitingPhase 2Laura Huppert, MD, BANCT03971409Written as Avelumab
- Targeted Therapy and Avelumab in Merkel Cell CarcinomaActive, not recruitingPhase 1/2Melanoma and Skin Cancer Trials LimitedNCT04261855Written as Avelumab
- Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial CarcinomaActive, not recruitingPhase 2Emory UniversityNCT04848519Written as Avelumab
- Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid TumorsActive, not recruitingPhase 1Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT03252938Written as Avelumab
- Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M CancersActive, not recruitingPhase 1/2TransgeneNCT03260023Written as Avelumab
Showing 20 of 38.
As the comparator · 2 — what is tested is compared with avelumab
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)Active, not recruitingPhase 2BicycleTx LimitedNCT06225596Written as Avelumab
- Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)CompletedPhase 3EMD Serono Research & Development Institute, Inc.NCT02625623Written as Avelumab
Codes
What other systems call avelumab · ClinicalTrials.gg INT000497
- MeSH (NLM) C000609138avelumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) KXG2PJ551IAVELUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1875534Confirmed FDA, Wikidata
- Wikidata Q21083261avelumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C116870AvelumabOne source FDA
- DrugBank DB11945One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000609138 | avelumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | KXG2PJ551I | AVELUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1875534 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21083261 | avelumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C116870 | Avelumab | One source FDA |
| DrugBank | DB11945 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.